Recent advancements in treating aggressive brain and spinal cord tumors in young patients have emerged from a clinical trial that demonstrates the efficacy of CAR-T cell therapy. Conducted by researchers at Stanford University, this trial aimed to evaluate the safety and effectiveness of this innovative approach in targeting lethal cancers such as diffuse midline gliomas, particularly prevalent in children and young adults. These tumors are notoriously aggressive, with a median survival time of only about a year. Out of the 11 participants in the trial, nine exhibited notable clinical improvements, including four whose tumors reduced significantly by 52 to 100 percent. One participant, diagnosed with diffuse intrinsic pontine glioma (DIPG), a particularly lethal form of brain cancer with a dismal five-year survival rate, achieved a complete response with no detectable tumor remaining after treatment.
The encouraging results have sparked hope in the medical community regarding a disease that is often deemed universally lethal. Dr. Michelle Monje, the lead author of the study, emphasized the significance of having developed a therapy that can yield substantial tumor regressions. She expressed optimism regarding one participant’s complete response, hoping it may indicate a potential cure. Nevertheless, there are considerable hurdles to overcome, as it is still early to determine long-term outcomes and the best strategies to optimize treatment for a broader range of patients. The study highlights the urgent need for continued research to understand the individual factors that influence the varied responses to this therapy.
The CAR-T cell therapy in question operates by extracting a patient’s T cells and genetically engineering them to target a specific molecular marker known as GD2, which is found in certain aggressive tumors. This approach builds upon earlier research conducted at Stanford in 2018, which identified GD2 levels in malignant brain and spinal cancers. After the engineering process, the modified T cells—known as chimeric antigen receptor T cells—are reintroduced into the patient’s body, where they prompt an immune reaction to attack the cancer. While CAR-T cell therapy has garnered regulatory approval for treating blood cancers, its application to solid tumors such as those found in the brain is a newer frontier.
Initial findings from the trials were published in an issue of the journal Nature and reveal the potential for CAR-T therapy to alleviate severe symptoms associated with tumors, which can lead to significant disabilities as the disease progresses. Dr. Stephen Bagley, an expert in hematology-oncology and neurosurgery, who was not involved in the study, commented on the exciting prospects that have emerged from these therapies for both pediatric and adult brain cancers. However, he also cautioned about the limitations of CAR-T treatment, noting that its effectiveness is not uniform across patients and some may not respond at all. He highlighted the necessity to explore the predictors of treatment success more comprehensively.
While the study’s results are promising, side effects such as fever, low blood pressure, and neurotoxicity—often tied to inflammation in the brain—present ongoing challenges. Dr. Bagley pointed out that managing toxicity is one of the current limitations of CAR-T therapy. The research community must develop strategies to mitigate these negative effects, allowing for the possibility of tolerating transient toxicity if it leads to meaningful clinical benefits. One participant in the trial reported a median survival of 20.6 months after diagnosis, with another participant, Drew, thriving four years post-treatment and marking a significant success story.
As the trial progresses, researchers are committed to differentiating the factors contributing to participants who showed the best treatment responses. Continuous refinement of the therapy is critical as new participants enroll. Dr. Crystal Mackall, a professor specializing in pediatrics and medicine at Stanford, reiterated the commitment to minimizing treatment toxicity while enhancing its efficacy. Dr. Bagley echoed this sentiment, emphasizing the field’s goal of optimizing CAR-T therapies to increase the rate of favorable responses and extend the durability of those responses. The proactivity in advancing these treatments fosters optimism that CAR-T therapies might gain approval for brain cancer treatment within the next few years, marking a significant milestone in pediatric oncology.
